SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates9/19/2013 10:33:02 AM
   of 1022
 
LONDON, Sept 19 (Reuters) - Britain's GlaxoSmithkline said it had signed a new four-year deal worth $196 million to supply the U.S. government with its inhalation anthrax treatment, raxibacumab, in case of a potential bio-terrorist attack.
GSK said on Thursday that it would supply 60,000 doses of the treatment to the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services...

(developed by CAT / HGSI)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News